Talphera, Inc. (TLPH)Healthcare | Drug Manufacturers - Specialty & Generic | San Mateo, United States | NasdaqCM
1.42 USD
-0.04
(-2.740%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.39 -0.03 (-0.026%) ⇩ (July 13, 2026, 6:49 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:40 a.m. EDT
The investment case for Talphera is effectively zero due to a catastrophic breakdown in both business fundamentals and market structure. The company is trapped in a multi-year death spiral, having lost 99% of its value over the last nine years with four consecutive years of negative annual returns. Fundamentally, the business is bleeding cash with negative operating margins of -14,516%, negative free cash flow, and a return on equity of -118%. The balance sheet is fragile, with debt-to-equity exceeding 35x and no cash generation to service obligations or fund operations. Despite a recent price rally from $0.98 to $1.46, this is a classic 'dead cat bounce' driven by low float and speculative trading, not a reversal of fortunes. The rally has been fueled by a single analyst initiation, which is insufficient to overcome the structural rot. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further declines while ignoring the near-term upside. There is no sustainable path to profitability visible in the data, and the valuation metrics (negative P/E, massive P/S) reflect a total lack of market confidence. This is a value trap where the low price is a warning sign, not a bargain. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.153284 |
| AutoETS | 0.153354 |
| AutoARIMA | 0.154087 |
| AutoTheta | 0.241106 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 3.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.112 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 35.172 |
| Market Cap | 73,697,496 |
| Forward P/E | -5.26 |
| Beta | 0.70 |
| Previous Name | AcelRx Pharmaceuticals, Inc. |
| Website | https://talphera.com |
As of July 11, 2026, 4:40 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across expirations, with heavy concentration in out-of-the-money strikes (1.0 and 1.5) suggesting a fear of further collapse. Call activity is sparse and concentrated at very distant strikes (5.0), indicating speculative lottery tickets rather than genuine bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.106383 |
| Address1 | 1,850 Gateway Drive |
| Address2 | Suite 175 |
| All Time High | 272.8 |
| All Time Low | 0.38 |
| Ask | 1.39 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 627,820 |
| Average Daily Volume3 Month | 251,772 |
| Average Volume | 251,772 |
| Average Volume10Days | 627,820 |
| Beta | 0.704 |
| Bid | 1.39 |
| Bid Size | 1 |
| Book Value | 0.345 |
| City | San Mateo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.42 |
| Current Ratio | 5.301 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.4698 |
| Day Low | 1.37 |
| Debt To Equity | 35.172 |
| Display Name | Talphera |
| Earnings Call Timestamp End | 1,778,704,200 |
| Earnings Call Timestamp Start | 1,778,704,200 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 59,088.5 |
| Enterprise Value | 59,088,500 |
| Eps Current Year | -0.255 |
| Eps Forward | -0.27 |
| Eps Trailing Twelve Months | -0.28 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.9322 |
| Fifty Day Average Change | 0.48779994 |
| Fifty Day Average Change Percent | 0.5232782 |
| Fifty Two Week Change Percent | 210.6383 |
| Fifty Two Week High | 1.57 |
| Fifty Two Week High Change | -0.1500001 |
| Fifty Two Week High Change Percent | -0.09554146 |
| Fifty Two Week Low | 0.38 |
| Fifty Two Week Low Change | 1.04 |
| Fifty Two Week Low Change Percent | 2.7368422 |
| Fifty Two Week Range | 0.38 - 1.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,297,434,600,000 |
| Float Shares | 26,980,551 |
| Forward Eps | -0.27 |
| Forward P E | -5.2592587 |
| Free Cashflow | -5,759,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -726,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21415001 |
| Held Percent Institutions | 0.34759 |
| Implied Shares Outstanding | 51,899,648 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,666,742,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. |
| Long Name | Talphera, Inc. |
| Market | us_market |
| Market Cap | 73,697,496 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_33172220 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -14,253,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 75,773,486 |
| Number Of Analyst Opinions | 3 |
| Open | 1.44 |
| Operating Cashflow | -11,294,000 |
| Operating Margins | -14,516.0 |
| Payout Ratio | 0.0 |
| Phone | 650 216 3500 |
| Post Market Change | -0.025999904 |
| Post Market Change Percent | -1.8309792 |
| Post Market Price | 1.394 |
| Post Market Time | 1,783,982,965 |
| Prev Name | AcelRx Pharmaceuticals, Inc. |
| Previous Close | 1.46 |
| Price Eps Current Year | -5.5686274 |
| Price Hint | 4 |
| Price To Book | 4.115942 |
| Price To Sales Trailing12 Months | 73,697.49 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.244 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0400001 |
| Regular Market Change Percent | -2.73973 |
| Regular Market Day High | 1.4698 |
| Regular Market Day Low | 1.37 |
| Regular Market Day Range | 1.37 - 1.4698 |
| Regular Market Open | 1.44 |
| Regular Market Previous Close | 1.46 |
| Regular Market Price | 1.42 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 488,648 |
| Return On Assets | -0.40188 |
| Return On Equity | -1.18395 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 51,899,648 |
| Shares Percent Shares Out | 0.0108 |
| Shares Short | 562,610 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 909,780 |
| Short Name | Talphera, Inc. |
| Short Percent Of Float | 0.0134000005 |
| Short Ratio | 2.3 |
| Source Interval | 15 |
| State | CA |
| Symbol | TLPH |
| Target High Price | 3.5 |
| Target Low Price | 3.0 |
| Target Mean Price | 3.16667 |
| Target Median Price | 3.0 |
| Total Cash | 21,108,000 |
| Total Cash Per Share | 0.407 |
| Total Debt | 6,499,000 |
| Total Revenue | 1,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.9964 |
| Two Hundred Day Average Change | 0.42359996 |
| Two Hundred Day Average Change Percent | 0.42513043 |
| Type Disp | Equity |
| Volume | 488,648 |
| Website | https://talphera.com |
| Zip | 94,404 |